Nicotine replacement liquid preparation, and preparation method therefor and use thereof

Abstract

The present application relates to the technical field of electronic atomization, and specifically relates to a nicotine replacement liquid preparation, and a preparation method therefor and the use thereof. In the nicotine replacement liquid preparation provided in the present application, the raw material components of the nicotine replacement liquid preparation comprise an additive capable of simulating the throat-hit sensation of nicotine, an additive capable of simulating the head-rush sensation of nicotine, and an atomization solvent. The additive capable of simulating the throat-hit sensation of nicotine is selected from at least one of piperine and 6-methylnicotine; and the additive capable of simulating the head-rush sensation of nicotine is selected from at least one of cytisine, magnolol and 6-methylnicotine. The nicotine replacement liquid preparation of the present application simulates the head-rush sensation and throat-hit sensation brought about by nicotine, enhances the head-rush sensation and throat-hit sensation of a nicotine-free atomization preparation, and improves the sense of satisfaction of a user, thereby achieving the aim of relieving addiction physiologically. Moreover, the toxicity and addictiveness of the nicotine replacement liquid preparation are both much lower than nicotine, such that damages to health can be reduced.

Description

Nicotine replacement liquid preparation, preparation method and application thereof

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to the Chinese patent application filed with the China Patent Office on December 8, 2023, with application number 202311688629.5 and invention name “A nicotine replacement liquid preparation, its preparation method and application”, the entire contents of which are incorporated herein by reference. Technical Field

[0003] The present application relates to the field of electronic atomization technology, and in particular to a nicotine replacement liquid preparation, a preparation method, and an application thereof. Background Art

[0004] An electronic nicotine atomizer is a smoking alternative that delivers nicotine without tobacco smoke. It operates by using a battery-powered atomizer to heat the e-liquid in the atomizer tank, allowing the consumer to inhale an aerosol containing or without nicotine, creating the same effect as smoking traditional tobacco products. Currently, electronic atomizer formulations typically contain propylene glycol, glycerol, flavorings, and nicotine, mixed in a specific ratio. Propylene glycol, glycerol, and flavorings are all permitted food additives. Compared to traditional cigarettes, electronic nicotine atomizers do not require combustion. The atomization process eliminates harmful substances such as tar, polycyclic aromatic hydrocarbons, and carbon monoxide produced by high-temperature combustion. Furthermore, they are virtually free of secondhand smoke, making them a promising nicotine substitute that can achieve a certain level of smoking cessation.

[0005] Electronic nicotine atomizers can be used as a means of relieving nicotine addiction. Nicotine is addictive and the primary substance that causes tobacco addiction, providing a physical relief for smokers. Furthermore, the inhalation behavior of electronic nicotine atomizers is similar to that of cigarettes, with puffs of smoke providing a psychological relief. However, nicotine is highly toxic and addictive, and long-term inhalation can affect human health. Currently, market regulation of nicotine is increasing, with countries beginning to limit the nicotine content in e-cigarettes to no more than 20mg / g. For public health and safety reasons, many countries are promoting zero-nicotine electronic atomizers, which are designed to eliminate the problem of nicotine addiction. Currently, the zero-nicotine atomizer formulations used in these devices primarily offer a rich, cooling effect. However, because they contain no nicotine, existing zero-nicotine atomizer formulations lack the throat hit and high associated with nicotine, resulting in a less satisfying product and a lack of physical relief.

[0006] Summary of the Invention

[0007] The purpose of this application is to overcome the defects of the existing zero-nicotine aerosol preparations in the art, such as the lack of throat hit and high feeling brought by nicotine, weak product satisfaction, and inability to relieve consumers' physiological addiction, and to provide a nicotine replacement liquid preparation and its preparation method and application.

[0008] To achieve the above objectives, this application adopts the following technical solutions:

[0009] The present application provides a nicotine replacement liquid preparation, wherein the raw material components of the nicotine replacement liquid preparation include a nicotine throat hit simulating additive, a nicotine head simulating additive, and an atomizing solvent;

[0010] The nicotine throat hit simulating additive is selected from at least one of piperine and 6-methylnicotine;

[0011] The nicotine high-sensation simulating additive is selected from at least one of cytisine, magnolol, and 6-methylnicotine.

[0012] Optionally, the total mass content of the nicotine throat hit simulating additive and the nicotine head simulating additive in the nicotine replacement liquid preparation is 2.1-61 mg / g.

[0013] Optionally, the mass ratio of the nicotine throat hit simulating additive to the nicotine head simulating additive is (0.1-11):(2-50).

[0014] Optionally, the raw material components of the nicotine replacement liquid preparation include 6-methylnicotine and an atomizing solvent.

[0015] Optionally, the mass ratio of the 6-methylnicotine to the atomizing solvent is (0.3-5):(40-95).

[0016] Optionally, the raw material components of the nicotine replacement liquid preparation include a nicotine throat hit simulating additive, a nicotine head simulating additive, and an atomizing solvent;

[0017] The nicotine throat hit simulating additive is selected from at least one of piperine and 6-methylnicotine;

[0018] The nicotine high-sensation simulating additive is selected from at least one of cytisine and magnolol.

[0019] Optionally, when the nicotine throat hit simulating additive is piperine, the nicotine head simulating additive is cytisine and / or magnolol;

[0020] Alternatively, when the nicotine throat hit simulating additive is 6-methylnicotine, the nicotine head simulating additive is cytisine and / or magnolol.

[0021] Optionally, when the nicotine throat hit simulating additive is piperine, the nicotine head feeling simulating additive is cytisine and magnolol, and the mass ratio of cytisine and magnolol is (5-40): (5-30);

[0022] Alternatively, when the nicotine throat hit simulating additive is 6-methylnicotine, the nicotine head simulating additive is cytisine and magnolol, and the mass ratio of cytisine and magnolol is (1-25):(1-5).

[0023] Optionally, the mass ratio of the total mass of the nicotine throat hit simulating additive and the nicotine head simulating additive to the atomizing solvent is (0.3-5):(40-95).

[0024] Optionally, the atomizing solvent includes at least one of propylene glycol and glycerol.

[0025] Optionally, the atomizing solvent is propylene glycol and glycerol;

[0026] The mass ratio of the propylene glycol to the glycerol is (1-50):(1-50).

[0027] Optionally, the mass content of the nicotine throat hit simulating additive in the nicotine replacement liquid preparation is 0.1-11 mg / g, and the mass content of the nicotine head simulating additive is 2-50 mg / g;

[0028] Optionally, the raw material components of the nicotine replacement liquid preparation further include an organic acid.

[0029] Optionally, the organic acid includes at least one of C3-C8 organic carboxylic acids;

[0030] Optionally, the organic acid includes at least one of C3-C8 monobasic organic carboxylic acid, C3-C8 dibasic organic carboxylic acid, and C3-C8 tribasic organic carboxylic acid.

[0031] Optionally, the organic acid includes at least one of salicylic acid, citric acid, malic acid, benzoic acid, levulinic acid, tartaric acid, and succinic acid;

[0032] Optionally, the organic acid is benzoic acid.

[0033] Optionally, the molar ratio of the organic acid to the 6-methylnicotine is 1:(0.98-1.5) based on the carboxyl group of the organic acid;

[0034] Optionally, the molar ratio of the organic acid to the molar ratio of 6-methylnicotine is 1:1, calculated based on the carboxyl group of the organic acid.

[0035] Optionally, the raw material components of the nicotine replacement liquid preparation further include flavors.

[0036] Optionally, the flavor includes at least one of tobacco flavor, fruit flavor, and mint flavor;

[0037] Optionally, the fruit flavor includes at least one of mango flavor, blueberry flavor, and grape flavor.

[0038] Optionally, the mass ratio of the total mass of the nicotine throat hit simulating additive and the nicotine head simulating additive to the flavor is (0.3-5):(20-45).

[0039] The nicotine replacement liquid preparation described in this application is used to enhance satisfaction, and further, to enhance consumer satisfaction.

[0040] The present application provides a method for preparing the nicotine replacement liquid preparation as claimed in the claim above, comprising the following steps:

[0041] The nicotine throat hit simulating additive, the nicotine head feeling simulating additive and the atomizing solvent are mixed, and then heated and stirred to obtain the product.

[0042] Optionally, the method for preparing the nicotine replacement liquid preparation further comprises the step of adding flavoring.

[0043] Optionally, the method for preparing the nicotine replacement liquid preparation further comprises the step of adding an organic acid.

[0044] The present application does not specifically limit the stirring method. Optionally, the stirring method is selected from mechanical stirring, mechanical oscillation or ultrasonic oscillation.

[0045] The present application provides a use of the above-mentioned nicotine replacement liquid preparation or the nicotine replacement liquid preparation prepared by the above-mentioned preparation method in an atomization device.

[0046] Optionally, the atomization device is an electronic atomization device.

[0047] Beneficial effects of this application:

[0048] The nicotine replacement liquid preparation provided herein comprises raw material components including a nicotine throat hit simulating additive, a nicotine head simulating additive, and an atomizing solvent; the nicotine throat hit simulating additive is selected from at least one of piperine and 6-methylnicotine; and the nicotine head simulating additive is selected from at least one of cytisine, magnolol, and 6-methylnicotine. The nicotine head-rush simulating additive (at least one of cytisine, magnolol, and 6-methylnicotine) of the present application can make the brain produce a head-rush effect similar to that of nicotine, and can partially replace the activating effect of nicotine. The nicotine throat hit simulating additive (at least one of piperine and 6-methylnicotine) can cause pain, irritation, numbness and itching in the human throat, forming a throat hit feeling. Among them, 6-methylnicotine has certain effects similar to the head-rush feeling and throat hit of nicotine. Therefore, the specific nicotine throat hit simulating additive and the nicotine head-rush simulating additive are compounded with the atomization solvent in a specific proportion to form a nicotine replacement liquid preparation, which synergistically simulates the head-rush feeling and throat hit feeling caused by nicotine, improves the head-rush feeling and throat hit feeling of the zero-nicotine atomization preparation, and enhances the user's satisfaction, thereby achieving the purpose of physiological addiction relief. At the same time, its toxicity and addictiveness are far lower than nicotine, which can reduce health damage. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] In order to more clearly illustrate the specific implementation methods of the present application or the technical solutions in the prior art, the following is a brief introduction to the drawings required for use in the specific implementation methods or the description of the prior art. Obviously, the drawings described below are some implementation methods of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without any creative work.

[0050] FIG1 is a graph of average normalized heart rates of Example 1, Example 2, Example 11, and Comparative Example 1 of the present application;

[0051] Figure 2 is a normalized heart rate diagram of Example 1, Example 2, Example 11, and Comparative Example 1 of the present application. DETAILED DESCRIPTION

[0052] The following examples are provided to further better understand the present application, but are not limited to the best implementation mode described herein, and do not limit the content and protection scope of the present application. Any product identical or similar to the present application obtained by anyone under the inspiration of the present application or by combining the features of the present application with other prior arts shall fall within the scope of protection of the present application.

[0053] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in this field can be used. If the manufacturer of the reagents or instruments is not specified, they are all commercially available conventional reagents.

[0054] The core ingredient in nicotine liquid preparations is nicotine. When the power source heats the atomizer, the nicotine in the nicotine liquid preparation is atomized into an aerosol and then inhaled by the human body. Part of the aerosol is transmitted to the throat, stimulating the throat and causing a throat hit. Another part of the aerosol enters the lungs and participates in the pulmonary venous circulation. Then it enters the arterial circulation, rapidly transmitting nicotine to the brain, where it binds to the acetylcholine receptors in the brain and promotes the release of neurotransmitters (dopamine). Dopamine release is a pleasurable experience that enhances the brain's reward function, produces a high, and gives smokers a sense of satisfaction. However, nicotine is highly toxic and addictive, and long-term inhalation can affect human health. Satisfaction is a comprehensive evaluation of the high and throat hit. An appropriate throat hit can help improve overall satisfaction, but an excessive throat hit can cause excessive inhalation irritation and physical discomfort, reducing satisfaction. Currently, to prevent nicotine abuse and protect public health and safety, countries around the world are implementing strict nicotine regulations on e-cigarette products, prompting many to promote zero-nicotine products to combat nicotine addiction. Zero-nicotine aerosol products primarily offer a rich, cooling effect. However, because they contain no nicotine, existing zero-nicotine aerosol products lack the throat hit and high associated with nicotine, resulting in a weaker sense of satisfaction and a failure to physically relieve consumers' addiction.

[0055] Cytisine is a natural bioactive compound isolated primarily from leguminous plants (particularly the seeds of honeysuckle) and is used as an adjunct to the clinical management of smoking cessation. Cytisine's primary target is neuronal nicotinic acetylcholine receptors (nAChRs), where binding to these receptors produces neurotransmitters such as dopamine, similar to the effects of nicotine.

[0056] Magnolia officinalis is the main active ingredient in Magnolia officinalis extract. Magnolia officinalis is a traditional Chinese medicine with diverse pharmacological activities. In recent years, research on magnolia officinalis has continued to deepen both domestically and internationally. Studies have found that magnolia officinalis has a wide range of pharmacological effects, including antidepressant effects, regulation of monoamine neurotransmitter activity, anti-inflammatory effects, and neuroprotective effects. Furthermore, magnolia officinalis can increase serotonin and dopamine levels in the frontal cortex of mice.

[0057] 6-Methylnicotine (CAS: 13270-56-9) is a synthetic organic compound and a nicotine analogue with a throat hit very similar to nicotine. The inventors have found that the throat hit of 6-methylnicotine is very noticeable in the subjective puff experience. The affinity of nicotine substitutes for nicotinic acetylcholine receptors (nAChRs) is related to the lipophilicity of the 6-position substituent. Related research further shows that as the size of the substituent increases, the affinity decreases. The affinity of nicotine analogs is determined by the lipophilicity of the 6-position substituent and is also related to the size of the substituent. Among them, the 6-position substituent of 6-methylnicotine is the smallest and most lipophilic, and it also has a strong affinity for nAChR receptors. Therefore, 6-methylnicotine can produce a high similar to nicotine.

[0058] Piperine is an alkaloid responsible for pepper's pungency and its most important bioactive component. It is a modulator of human transient receptor potential (TRP) channels. Activating these channels can cause pain, irritation, numbness, and itching in the throat, creating a throat hit similar to nicotine. Furthermore, scientific research has shown that piperine inhibits enzymes important in drug metabolism. By inhibiting drug metabolism, piperine may increase the bioavailability of many compounds, thereby enhancing the bioactivity of other alkaloids in the human body and helping to enhance the feeling of a high.

[0059] The inventors unexpectedly discovered that piperine and 6-methylnicotine can be used as additives to simulate the throat hit of nicotine, and cytisine, magnolol, and 6-methylnicotine can be used as additives to simulate the nicotine head feeling. By properly combining different combinations of the nicotine throat hit simulating additives and the nicotine head feeling simulating additives, they can synergistically simulate the throat hit and head feeling brought by nicotine, thereby improving the throat hit and head feeling of zero-nicotine products and producing a high sense of satisfaction.

[0060] The present application provides a nicotine replacement liquid preparation, the raw material components of which include a nicotine throat hit simulating additive, a nicotine head simulating additive, and an atomizing solvent; the nicotine throat hit simulating additive is selected from at least one of piperine and 6-methylnicotine; and the nicotine head simulating additive is selected from at least one of cytisine, magnolol, and 6-methylnicotine. The inventors discovered that nicotine head-rush simulating additives (at least one of cytisine, magnolol, and 6-methylnicotine) can induce a head-rush effect similar to nicotine in the brain, and can partially replace the activating effect of nicotine. Nicotine throat-hit simulating additives (at least one of piperine and 6-methylnicotine) can cause pain, irritation, numbness, itching, and other sensations in the human throat, forming a throat-hit sensation. 6-methylnicotine also has certain head-rush and throat-hit effects similar to nicotine. Therefore, a nicotine replacement liquid preparation formed by compounding a specific nicotine throat-hit simulating additive and a nicotine head-rush simulating additive with an atomization solvent in a specific ratio synergistically simulates the head-rush and throat-hit sensations caused by nicotine, thereby enhancing the head-rush and throat-hit sensations of the zero-nicotine atomization preparation and increasing the user's sense of satisfaction, thereby achieving the purpose of physiological addiction relief. At the same time, its toxicity and addictiveness are far lower than nicotine, which can reduce health damage.

[0061] In some optional embodiments, the total mass content of the nicotine throat hit simulating additive and the nicotine head simulating additive in the nicotine replacement liquid preparation is 2.1-61 mg / g. For example, the total mass content of the nicotine throat hit simulating additive and the nicotine head simulating additive in the nicotine replacement liquid preparation can be 2.1 mg / g, 2.5 mg / g, 2.6 mg / g, 3 mg / g, 3.5 mg / g, 4 mg / g, 4.5 mg / g, 5 mg / g, 5.6 mg / g, 6 mg / g, 7 mg / g, 8 mg / g, 9 mg / g, 10 mg / g, 11 mg / g, 12 mg / g, 13 mg / g, 14 mg / g, 15 mg / g, 16 mg / g, 17 mg / g, 18 mg / g, 19 mg / g, 20 mg / g, 22 mg / g, 23 mg / g, 24 mg / g. g / g, 25mg / g, 26mg / g, 27mg / g, 28mg / g, 29mg / g, 30mg / g, 31mg / g, 32mg / g, 33mg / g, 34mg / g, 35mg / g, 36mg / g, 37mg / g, 38mg / g, 39mg / g, 40mg / g, 4 1mg / g, 42mg / g, 43mg / g, 44mg / g, 45mg / g, 46mg / g, 47mg / g, 48mg / g, 49mg / g, 50mg / g, 51mg / g, 52mg / g, 53mg / g, 54mg / g, 55mg / g, 56mg / g, 57mg / g, 58mg / g, 59mg / g, 60mg / g, 61mg / g.

[0062] In some optional embodiments, the mass ratio of the nicotine throat hit simulation additive to the nicotine head feeling simulation additive is (0.1-11):(2-50); for example, the mass ratio of the nicotine throat hit simulation additive to the nicotine head feeling simulation additive can be: 0.1:2, 0.1:3, 0.1:5, 0.1:9, 0.1:10, 0.1:15, 0.1:19, 0.1:20, 0.1:25, 0.1:26, 0.1:30, 0.1:35, 0.1:37, 0.1:40, 0.1:45, 0.1:50, 0.5:2, 0.5:3, 0.5:5, 0.5:9 , 0.5:10, 0.5:15, 0.5:19, 0.5:20, 0.5:25, 0.5:26, 0.5:30, 0.5:35, 0.5:37, 0.5:40, 0.5:45, 0.5:50, 1:2, 1:3, 1:5, 1:9, 1:10, 1:15, 1:19, 1:20, 1:25, 1:26, 1:30, 1:35, 1:37, 1:40, 1:45, 1:50, 3:2, 3:3, 3:5, 3:9, 3:10, 3:15, 3:19, 3:20, 3:25, 3:26, 3:30, 3:35, 3:37, 3:40, 3 :45, 3:50, 5:2, 5:3, 5:5, 5:9, 5:10, 5:15, 5:19, 5:20, 5:25, 5:26, 5:30, 5:35, 5:37, 5:40, 5:45, 5:50, 7:2, 7:3, 7:5, 7:9, 7:10, 7:15, 7:19, 7:20, 7:25, 7:26, 7:30, 7:35, 7:37, 7:40, 7:45, 7:50, 10:2, 10:3, 10:5, 10:9, 10:10, 10:15, 10:19, 10:20, 10:25, 10:26, 10:30, 10:3 The inventors found that by controlling the mass ratio of the nicotine throat hit simulating additive and the nicotine head simulating additive within the range of (0.1-11): (2-50), under their synergistic effect, the user's satisfaction is improved, and the satisfaction can reach or even exceed that of the commercial product with benzoic acid as the organic acid and a nicotine content of 10 mg / g.

[0063] The raw materials of the nicotine replacement liquid preparation include 6-methyl nicotine and an atomizing solvent. The inventors have discovered that 6-methyl nicotine has both a high and throat hit similar to nicotine, significantly improving user satisfaction and even surpassing nicotine. Furthermore, its toxicity and addictiveness are far lower than nicotine, reducing harm to human health.

[0064] In some optional embodiments, the mass ratio of 6-methyl nicotine to the atomizing solvent is (0.3-5):(40-95). For example, the mass ratio of 6-methyl nicotine to the atomizing solvent can be 0.3:40, 0.3:45, 0.3:47, 0.3:50, 0.3:51, 0.3:55, 0.3:60, 0.3:65, 0.3:70, 0.3:74, 0.3:80, 0.3:85, 0.3:90, 0.3:95, 0.5:40, 0.5:45, 0.5:50, 0.5:51, 0.5:55, 0.5:60, 0.5:65, 0.5:70, 0.5:74, 0.5:80, 0.5: 85, 0.5:90, 0.5:95, 1:40, 1:45, 1:47, 1:50, 1:51, 1:55, 1:60, 1:65, 1:70, 1:74, 1:80, 1:85, 1:90, 1:95, 1.5:40, 1.5:45, 1.5:47, 1.5:50, 1.5:51, 1.5:55, 1.5:60, 1.5:65, 1.5:70, 1.5:74, 1.5:80, 1.5:85, 1.5:90, 1.5:95, 2:40, 2:45, 2:47, 2: 50, 2:51, 2:55, 2:60, 2:65, 2:70, 2:74, 2:80, 2:85, 2:90, 2:95, 3:40, 3:45, 3:47, 3:50, 3:51, 3:55, 3:60, 3:65, 3:70, 3:74, 3:80, 3:85, 3:90, 3:95, 4:40, 4:4 5, 4:47, 4:50, 4:51, 4:55, 4:60, 4:65, 4:70, 4:74, 4:80, 4:85, 4:90, 4:95, 5:40, 5:45, 5:47, 5:50, 5:51, 5:55, 5:60, 5:65, 5:70, 5:74, 5:80, 5:85, 5:90, 5:95.

[0065] In some optional embodiments, the raw material components of the nicotine replacement liquid preparation include a nicotine throat hit simulating additive, a nicotine head simulating additive, and an atomizing solvent; the nicotine throat hit simulating additive is selected from at least one of piperine and 6-methylnicotine; and the nicotine head simulating additive is selected from at least one of cytisine and magnolol.

[0066] In some optional embodiments, the nicotine throat hit simulating additive is piperine, and the nicotine head simulating additive is cytisine. In some optional embodiments, the nicotine throat hit simulating additive is piperine, and the nicotine head simulating additive is magnolol. In other optional embodiments, the nicotine throat hit simulating additive is piperine, and the nicotine head simulating additive is cytisine and magnolol.The mass ratio of cytisine and magnolol is (5-40): (5-30). For example, the mass ratio of cytisine and magnolol can be selected as 5:5, 5:6, 5:8, 10, 5:11, 5:13, 5:15, 5:17, 5:19, 5:20, 5:21, 5:23, 5:25, 5:26, 5:28, 5:29, 5:30, 7:5, 7:6, 7:8, 10, 7:11, 7:13, 7:15, 7:17, 7:19, 7:20, 7:21, 7:23, 7:25, 7:26, 7:28, 7:29, 7:30, 10:5, 10:6, 10:8, 10, 10:11, 10:13, 10:15, 10:17, 10:19, 10:20, 10:21, 10:23, 10:25, 10:26, 10:28, 10:29, 10:30, 15:5, 15:6, 15:8, 10, 15:11, 15:13, 15:15, 15:17, 15:19, 15:20, 15:21, 15:23, 15:25, 15:26, 15:28, 15:29, 15:30, 20:5, 20:6, 20:8, 10, 20:11, 20:13, 20:15, 20: 17, 20:19, 20:20, 20:21, 20:23, 20:25, 20:26, 20:28, 20:29, 20:30, 25:5, 25:6, 25:8, 10, 25:11, 25:13, 25:15, 25:17, 25:19, 25:20, 25:21, 25:23, 25:25, 25:26, 25:28, 25:29, 25:30, 30:5, 30:6, 30:8, 10, 30:11, 30:13, 30:15, 30:17, 30:19, 30:20, 30:21, 30:23, 3 :25, 30:26, 30:28, 30:29, 30:30, 35:5, 35:6, 35:8, 10, 35:11, 35:13, 35:15, 35:17, 35:19, 35:20, 35:21, 35:23, 35:25, 35:26, 35:28, 35:29, 35:30, 40:5, 40:6, 40:8, 10, 40:11, 40:13, 40:15, 40:17, 40:19, 40:20, 40:21, 40:23, 40:25, 40:26, 40:28, 40:29, 40:30. The combination of piperine, cytisine, and magnolol significantly improves user satisfaction compared to the combination of cytisine and piperine alone or the combination of magnolol and piperine alone.

[0067] In some optional embodiments, the nicotine throat hit simulation additive is 6-methylnicotine, and the nicotine head feeling simulation additive is cytisine. In some optional embodiments, the nicotine throat hit simulation additive is 6-methylnicotine, and the nicotine head feeling simulation additive is magnolol. In other optional embodiments, the nicotine throat hit simulation additive is 6-methylnicotine, and the nicotine head feeling simulation additive is cytisine and magnolol. The mass ratio of cytisine and magnolol is (1-25): (1-5). For example, the mass ratio of cytisine and magnolol can be selected from 1:1, 2:1, 5:1, 7:1, 9:1, 10:1, 12:1, 13:1, 15:1, 18:1, 19:1, 20:1, 21:1, 24:1, 25:1, 1:2, 2:2, 5:2, 7:2, 9:2, 10:2, 12:2, 13:2, 15:2, 18:2, 19:2, 20:2, 21:2, 24:2, 25:2, 1:3, 2:3, 5:3, 7:3, 9:3, 10:3, 12:3, 13:3, 15:3, 18:3, 19:3, 20:3, 21:3, 24:3, 25:3, 1: 4, 2:4, 5:4, 7:4, 9:4, 10:4, 12:4, 13:4, 15:4, 18:4, 19:4, 20:4, 21:4, 24:4, 25:4, 1:5, 2:5, 5:5, 7:5, 9:5, 10:5, 12:5, 13:5, 15:5, 18:5, 19:5, 20:5, 21:5, 24:5, 25:5. The combination of 6-methylnicotine, cytisine, and magnolol significantly improves user satisfaction compared to the combination of cytisine and 6-methylnicotine alone or the combination of magnolol and 6-methylnicotine alone.

[0068] In some optional embodiments, the atomizing solvent may be a conventional atomizing solvent in the art, including but not limited to at least one of propylene glycol and glycerol; optionally, the mass ratio of the total mass of the nicotine throat hit simulation additive and the nicotine head feeling simulation additive to the atomizing solvent is (0.3-5): (40-95), for example, the mass ratio of the total mass of the nicotine throat hit simulation additive and the nicotine head feeling simulation additive to the atomizing solvent can be selected to be 0.3:40, 0.3:45, 0.3:47, 0.3:50, 0.3:51, 0.3:5 5. 0.3:60, 0.3:65, 0.3:70, 0.3:74, 0.3:80, 0.3:85, 0.3:90, 0.3:95, 0.5:40, 0.5:45, 47, 0.5:50, 0.5:51, 0.5:55, 0.5:60, 0.5:65, 0.5:70, 0.5:74, 0.5:80, 0.5:85, 0.5:90, 0.5:95, 1:40, 1:45, 1:47, 1:50, 1:51, 1:55, 1:60, 1:65, 1:70, 1: 74, 1:80, 1:85, 1:90, 1:95, 1.5:40, 1.5:45, 1.5:47, 1.5:50, 1.5:51, 1.5:55, 1.5:60, 1.5:65, 1.5:70, 1.5:74, 1.5:80, 1.5:85, 1.5:90, 1.5:95, 2:40, 2:45, 2:47, 2:50, 2:51, 2:55, 2:60, 2:65, 2:70, 2:74, 2:80, 2:85, 2:90, 2:95, 3:40, 3:4 : 55, 5:40, 5:45, 5:47, 5:50, 5:51, 5:55, 5:60, 5:65, 5:70, 5:74, 5:80, 5:85, 5:90, 5:95. Optionally, the atomizing solvent is propylene glycol and glycerol.The mass ratio of propylene glycol to glycerol is (1-50): (1-50). The mass ratio of propylene glycol to glycerol ethanol can be selected from 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:13, 1:15, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1:50, 2:1, 2:3, 2:5, 2:7, 2:9, 2:1 0, 2:13, 2:15, 2:20, 2:25, 2:30, 2:35, 2:40, 2:45, 2:50, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 12:1, 13:1, 15:1, 18:1, 20:1, 22:1, 25:1, 29:1, 30:1, 32:1, 35:1, 40:1, 43:1, 45:1, 47:1, 50:1. The addition of the atomizing solvent in this application can better dissolve the raw material components, effectively improve the atomization efficiency of nicotine, and increase the sense of satisfaction.

[0069] In some optional embodiments, the mass content of the nicotine throat hit simulating additive in the nicotine replacement liquid preparation is 0.1-11 mg / g, and the mass content of the nicotine head simulating additive is 2-50 mg / g. For example, the mass content of A in the nicotine replacement liquid preparation can be 0.1 mg / g, 0.5 mg / g, 0.7 mg / g, 0.9 mg / g, 1 mg / g, 1.1 mg / g, 1.5 mg / g, 1.7 mg / g, 2 mg / g, 2.3 mg / g, 2.5 mg / g, 2.7 mg / g, 3 mg / g, 3.5 mg / g, 3.7 mg / g, 4 mg / g, 4.5 mg / g, 4.8 The mass content of nicotine head-feeling simulation additives is 2mg / g, 3mg / g, 4mg / g, 5mg / g, 6mg / g, 7mg / g, 8mg / g, 9mg / g, 10mg / g, 11mg / g, and the mass content of nicotine head-feeling simulation additives is 2mg / g, 3mg / g, 4mg / g, 5mg / g, 6mg / g, 7mg / g, 8 ...0.5mg / g, 11mg / g. mg / g, 6mg / g, 7mg / g, 8mg / g, 9mg / g, 10mg / g, 11mg / g, 12mg / g, 13mg / g, 14mg / g, 15mg / g, 16mg / g, 1 7mg / g, 18mg / g, 19mg / g, 20mg / g, 21mg / g, 22mg / g, 23mg / g, 24mg / g, 25mg / g, 26mg / g, 27mg / g, 28m g / g, 29mg / g, 30mg / g, 31mg / g, 32mg / g, 33mg / g, 34mg / g, 35mg / g, 36mg / g, 37mg / g, 38mg / g, 39mg / g, 40mg / g, 41mg / g, 42mg / g, 43mg / g, 44mg / g, 45mg / g, 46mg / g, 47mg / g, 48mg / g, 49mg / g, 50mg / g.

[0070] In some optional embodiments, the raw material components of the nicotine replacement liquid formulation further include an organic acid. Optionally, the organic acid includes at least one of C3-C8 organic carboxylic acids; further optionally, the organic acid includes at least one of C3-C8 monocarboxylic acids, C3-C8 dicarboxylic acids, and C3-C8 tricarboxylic acids. Further optionally, the organic acid includes at least one of salicylic acid, citric acid, malic acid, benzoic acid, levulinic acid, tartaric acid, and succinic acid; further optionally, the organic acid is benzoic acid. By further adding a specific organic acid to the raw material components to form a nicotine salt, the present application can further ensure user satisfaction.

[0071] In some optional embodiments, the molar ratio of the organic acid, calculated as carboxyl groups, to the molar ratio of 6-methylnicotine is 1:(0.98-1.5); for example, the molar ratio of the organic acid, calculated as carboxyl groups, to the molar ratio of 6-methylnicotine can be 1:0.98, 1:0.99, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, or 1:1.5. After adding 6-methylnicotine to the nicotine head-feeling simulating additive and / or the nicotine throat-hit simulating additive, the inventors further discovered that the organic acid and its added amount affect the sense of satisfaction. Changing the molar ratio of the organic acid to 6-methylnicotine can change the acid-base environment of the throat and adjust the throat hit during the aerosol entering the lungs. Optionally, the molar ratio of the organic acid, calculated as carboxyl groups, to the molar ratio of 6-methylnicotine is 1:1.

[0072] In some optional embodiments, the raw material components of the nicotine replacement liquid preparation also include flavors. The flavors can be conventional existing flavor materials in the field, which can be obtained commercially or prepared by conventional methods using conventional components. For example, it can be selected from monomeric flavor raw materials or a variety of extracts. Including but not limited to tobacco flavors, fruit flavors, mint flavors. Furthermore, the fruit flavors include at least one of mango flavor, blueberry flavor, and grape flavor; optionally, the mass ratio of the total mass of the nicotine throat hit simulation additive and the nicotine head feeling simulation additive to the mass ratio of the flavor is (0.3-5): (20-45). For example, the mass ratio of the total mass of the nicotine throat hit simulation additive and the nicotine head feeling simulation additive to the mass ratio of the flavor can be 0.3:20, 0.3:25, 0.3:30, 0.3:35, 0.3:40, 0.3:45, 0.5:20, 0.5:25, 0.5:30, 0.5:35 , 0.5:40, 0.5:45, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1.5:20, 1.5:25, 1.5:30, 1.5:35, 1.5:40, 1.5:45, 2:20, 2:25, 2:30, 2:35, 2:40, 2:45, 3:20, 3:25, 3:30, 3:35, 3:40, 3:45, 4:20, 4:25, 4:30, 4:35, 4:40, 4:45, 5:20, 5:25, 5:30, 5:35, 5:40, 5:45.

[0073] The present application also provides a method for preparing the above-mentioned nicotine replacement liquid preparation, comprising the following steps: mixing a nicotine throat hit simulating additive, a nicotine head simulating additive, and an atomizing solvent, and then heating and stirring the mixture until uniform.

[0074] In some optional embodiments, the method for preparing the nicotine replacement liquid formulation further comprises the step of adding flavoring.

[0075] In some optional embodiments, the method for preparing the nicotine replacement liquid formulation further comprises the step of adding an organic acid.

[0076] This application does not make specific restrictions on the heating and stirring temperature and time, as long as the raw materials can be dissolved. Optionally, the dissolution temperature is not higher than 100°C. Optionally, the heating and stirring temperature is 40-65°C, and the heating and stirring time is 20-30min. This application does not make specific restrictions on the mixing method and the order of mixing. Optionally, in this application, all the raw materials can be mixed and then heated to dissolve, or some of the raw materials can be mixed and dissolved first, and then the remaining raw materials can be mixed and dissolved.

[0077] In some optional embodiments, the method for preparing the nicotine replacement liquid preparation comprises the following steps: mixing a nicotine head-simulating additive, a nicotine throat-hit simulating additive, an organic acid, and a portion of an atomizing solvent; heating at 40-65° C. for 20-30 minutes to dissolve and mix uniformly; cooling to 10-35° C.; adding flavoring and stirring for 5-40 minutes to mix uniformly, to obtain the nicotine replacement liquid preparation.

[0078] In some optional embodiments, the method for preparing the nicotine replacement liquid preparation comprises the following steps: mixing a nicotine head-simulating additive, a nicotine throat-hit simulating additive, an organic acid, and a portion of an atomizing solvent; heating at 40-65° C. for 20-30 minutes to dissolve and mix uniformly; cooling to room temperature; adding flavoring and stirring for 5-40 minutes to mix uniformly, to obtain the nicotine replacement liquid preparation.

[0079] The present application also provides a use of the aforementioned nicotine replacement liquid preparation or the nicotine replacement liquid preparation prepared by the aforementioned preparation method in an atomization device. Optionally, the atomization device is an electronic atomization device.

[0080] Example 1

[0081] This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

[0082] 0.6 g of 6-methylnicotine, 1 g of magnolol, 0.42 g of benzoic acid, 12.98 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine replacement liquid preparation.

[0083] Example 2

[0084] This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

[0085] 0.6 g of 6-methylnicotine, 1 g of cytisine, 0.42 g of benzoic acid, 12.98 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine replacement liquid preparation.

[0086] Example 3

[0087] This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

[0088] 0.01 g of piperine, 4.5 g of cytisine, 10.49 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine replacement liquid preparation.

[0089] Example 4

[0090] This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

[0091] 0.01 g of piperine, 4.5 g of magnolol, 10.49 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine replacement liquid preparation.

[0092] Example 5

[0093] This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

[0094] 3 g of cytisine, 1.5 g of magnolol, 0.01 g of piperine, 10.49 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine replacement liquid preparation.

[0095] Example 6

[0096] This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

[0097] 3.0 g of cytisine, 1.5 g of magnolol, 0.05 g of piperine, 10.45 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine replacement liquid preparation.

[0098] Example 7

[0099] This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

[0100] 3.0 g of cytisine, 1.5 g of magnolol, 0.1 g of piperine, 10.4 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine replacement liquid preparation.

[0101] Example 8

[0102] This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

[0103] 0.3 g of 6-methylnicotine, 0.21 g of benzoic acid, 14.49 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine replacement liquid preparation.

[0104] Example 9

[0105] This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

[0106] 0.6 g of 6-methylnicotine, 0.42 g of benzoic acid, 13.98 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine replacement liquid preparation.

[0107] Example 10

[0108] This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

[0109] 1.0 g of 6-methylnicotine, 0.69 g of benzoic acid, 13.31 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine replacement liquid preparation.

[0110] Example 11

[0111] This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

[0112] 0.6 g of 6-methylnicotine, 0.5 g of cytisine, 0.5 g of magnolol, 0.42 g of benzoic acid, 12.98 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine replacement liquid preparation.

[0113] Example 12

[0114] This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

[0115] 0.6 g of 6-methylnicotine, 3.0 g of cytisine, 1.5 g of magnolol, 0.42 g of benzoic acid, 9.48 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine replacement liquid preparation.

[0116] Example 13

[0117] 1.0 g of 6-methylnicotine, 3.0 g of cytisine, 1.5 g of magnolol, 0.69 g of benzoic acid, 8.81 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine replacement liquid preparation.

[0118] Comparative Example 1

[0119] This comparative example provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

[0120] 15 g of propylene glycol and 40 g of glycerol were mixed, stirred at 60° C. for 20 minutes to uniformly mix, and after cooling to room temperature, 45 g of blueberry essence was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine replacement liquid preparation.

[0121] Comparative Example 2

[0122] This comparative example provides a method for preparing a nicotine liquid preparation, comprising the following steps:

[0123] 1 g of nicotine, 0.75 g of benzoic acid, 13.25 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine liquid preparation.

[0124] Comparative Example 3

[0125] This comparative example provides a method for preparing a nicotine liquid preparation, comprising the following steps:

[0126] 2 g of nicotine, 1.5 g of benzoic acid, 11.5 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine liquid preparation.

[0127] Comparative Example 4

[0128] This comparative example provides a method for preparing a nicotine liquid preparation, comprising the following steps:

[0129] 3 g of nicotine, 2.26 g of benzoic acid, 9.74 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine liquid preparation.

[0130] Comparative Example 5

[0131] This comparative example provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

[0132] 3.0 g of cytisine, 12 g of propylene glycol, and 40 g of glycerol were mixed and stirred at 60° C. for 20 minutes to uniformly mix. After cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine replacement liquid preparation.

[0133] Comparative Example 6

[0134] This comparative example provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

[0135] 1.5 g of magnolol, 13.5 g of propylene glycol, and 40 g of glycerol were mixed, stirred at 60° C. for 20 minutes to uniformly mix, and after cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 minutes to uniformly mix, thereby obtaining the nicotine replacement liquid preparation.

[0136] Test Case

[0137] This application uses a subjective smoking method to score various smoking indicators of the liquid preparations of Examples 1-13 and Comparative Examples 1-6. The smoking team consists of 15 people, all of whom have more than three years of experience in smoking traditional cigarettes or e-cigarettes and have undergone nicotine withdrawal 10 hours before smoking.

[0138] Each smoker was given a smoking evaluation form and smoked the nicotine replacement liquid preparations or nicotine liquid preparations of different embodiments and comparative examples using a secret scoring method. The smoking method was as follows: the smoker withdrew nicotine for 10 hours the night before smoking, and conducted a smoking test at 9 am on the day of smoking. A total of 10 puffs of smoke were inhaled using a RELX5 generation electronic cigarette rod (with different embodiments and comparative examples) (3 seconds per puff, 27 seconds between each puff). After smoking, the smokers were scored and evaluated according to the evaluation indicators in Table 1. After smoking a sample of smoke oil, they withdrew for 2 hours and then conducted a smoking test of the next sample of smoke oil. The results of the smoking test are shown in Table 2 (the scoring value is the average score).

[0139] Table 1 Evaluation indicators

[0140] Table 2 Product absorption scoring data

[0141] The liquid preparations prepared in Example 1, Example 2, Example 11 and Comparative Example 1 (hereinafter referred to as samples) were subjected to a heart rate test during the smoking process. The test method is as follows: the smokers undergo nicotine withdrawal the night before the smoking test, and the heart rate test during the smoking process is performed at 9 a.m. on the day of smoking. Before smoking, the heart rate test instrument is worn (the heart rate test instrument is Lepu Xinanbao ER1), and the real-time changes in heart rate are monitored throughout the smoking process. After the heart rate instrument is worn and debugged, a 2-minute baseline heart rate test is performed. After the heart rate stabilizes, heart rate monitoring during the smoking process is started, using a RELX5 substitute cigarette rod (matched with samples of different embodiments and comparative examples), and a total of 5 puffs of smoke are inhaled (3 seconds per puff, with an interval of 27 seconds between adjacent puffs). The entire smoking process takes about 2.5 minutes, and the time when each puff of smoke starts is recorded. After the smoking is completed, the heart rate changes are monitored for another 1 minute, and then the experiment is terminated. After finishing one sample, abstain from smoking for 2 hours before testing the heart rate during the next sample. The test results are shown in Figures 1 and 2. The average normalized heart rate in Figure 1 is the ratio of the average monitored heart rate during smoking to the average baseline heart rate, while the normalized heart rate in Figure 2 is the ratio of the real-time monitored heart rate during smoking to the average baseline heart rate over the above 2 minutes.

[0142] Obviously, the above embodiments are merely examples for clarity of explanation and are not intended to limit the implementation methods. Those skilled in the art will readily appreciate that other variations or modifications based on the above descriptions are possible. It is not necessary and impossible to enumerate all implementation methods here. Obvious variations or modifications arising therefrom remain within the scope of protection of the present invention.

Claims

1. A nicotine replacement liquid preparation, characterized in that: The raw material components of the nicotine replacement liquid preparation include a nicotine throat hit simulating additive, a nicotine head simulating additive and an atomizing solvent; The nicotine throat hit simulating additive is selected from at least one of piperine and 6-methyl nicotine; The nicotine head-feeling simulating additive is selected from at least one of cytisine, magnolol, and 6-methylnicotine.

2. The nicotine replacement liquid preparation according to claim 1, characterized in that The total mass content of the nicotine throat hit simulating additive and the nicotine head simulating additive in the nicotine replacement liquid preparation is 2.1-61 mg / g.

3. The nicotine replacement liquid preparation according to claim 1 or 2, characterized in that The mass ratio of the nicotine throat hit simulation additive to the nicotine head feeling simulation additive is (0.1-11):(2-50).

4. The nicotine replacement liquid preparation according to any one of claims 1 to 3, characterized in that The raw material components of the nicotine replacement liquid preparation include 6-methyl nicotine and an atomizing solvent.

5. The nicotine replacement liquid preparation according to claim 4, characterized in that The mass ratio of the 6-methylnicotine to the atomizing solvent is (0.3-5):(40-95).

6. The nicotine replacement liquid preparation according to any one of claims 1 to 3, characterized in that The raw material components of the nicotine replacement liquid preparation include a nicotine throat hit simulating additive, a nicotine head simulating additive and an atomizing solvent; The nicotine throat hit simulating additive is selected from at least one of piperine and 6-methyl nicotine; The nicotine head feeling simulating additive is selected from at least one of cytisine and magnolol.

7. The nicotine replacement liquid preparation according to claim 6, characterized in that When the nicotine throat hit simulating additive is piperine, the nicotine head simulating additive is cytisine and / or magnolol; Alternatively, when the nicotine throat hit simulating additive is 6-methyl nicotine, the nicotine head simulating additive is cytisine and / or magnolol.

8. The nicotine replacement liquid preparation according to claim 7, characterized in that When the nicotine throat hit simulating additive is piperine, the nicotine head feeling simulating additive is cytisine and magnolol, and the mass ratio of cytisine and magnolol is (5-40):(5-30); Alternatively, when the nicotine throat hit simulating additive is 6-methyl nicotine, the nicotine head simulating additive is cytisine and magnolol, and the mass ratio of cytisine and magnolol is (1-25):(1-5).

9. The nicotine replacement liquid preparation according to any one of claims 1 to 8, characterized in that The mass ratio of the total mass of the nicotine throat hit simulation additive and the nicotine head feeling simulation additive to the atomization solvent is (0.3-5): (40-95).

10. The nicotine replacement liquid preparation according to any one of claims 1 to 9, characterized in that: The atomizing solvent includes at least one of propylene glycol and glycerol.

11. The nicotine replacement liquid preparation according to any one of claims 1 to 10, characterized in that: The atomizing solvent is propylene glycol and glycerol; The mass ratio of propylene glycol to glycerol is (1-50):(1-50).

12. The nicotine replacement liquid preparation according to any one of claims 1 to 11, characterized in that The mass content of the nicotine throat hit simulating additive in the nicotine replacement liquid preparation is 0.1-11 mg / g, and the mass content of the nicotine head simulating additive is 2-50 mg / g.

13. The nicotine replacement liquid preparation according to any one of claims 1 to 12, characterized in that The raw material components of the nicotine replacement liquid preparation also include an organic acid.

14. The nicotine replacement liquid preparation according to claim 13, characterized in that The organic acid includes at least one of C3-C8 organic carboxylic acids; Optionally, the organic acid includes at least one of C3-C8 monobasic organic carboxylic acid, C3-C8 dibasic organic carboxylic acid, and C3-C8 tribasic organic carboxylic acid.

15. The nicotine replacement liquid preparation according to claim 13 or 14, characterized in that The organic acid comprises at least one of salicylic acid, citric acid, malic acid, benzoic acid, levulinic acid, tartaric acid and succinic acid; Optionally, the organic acid is benzoic acid.

16. The nicotine replacement liquid preparation according to any one of claims 13 to 15, characterized in that The organic acid is calculated based on the carboxyl group, and the molar ratio of the organic acid to the molar ratio of 6-methylnicotine is 1:(0.98-1.5); Preferably, the molar ratio of the organic acid to the molar ratio of 6-methylnicotine is 1:1, calculated based on the carboxyl group of the organic acid.

17. The nicotine replacement liquid preparation according to any one of claims 1 to 16, characterized in that The raw material components of the nicotine replacement liquid preparation also include flavors.

18. The nicotine replacement liquid preparation according to claim 17, characterized in that The flavor includes at least one of tobacco flavor, fruit flavor, and mint flavor; Optionally, the fruit flavor includes at least one of mango flavor, blueberry flavor, and grape flavor.

19. The nicotine replacement liquid preparation according to claim 17 or 18, characterized in that The mass ratio of the total mass of the nicotine throat hit simulation additive and the nicotine head feeling simulation additive to the flavor is (0.3-5):(20-45).

20. A method for preparing the nicotine replacement liquid preparation according to any one of claims 1 to 19, characterized in that: The steps include: The nicotine throat hit simulating additive, the nicotine head feeling simulating additive and the atomizing solvent are mixed, and then heated and stirred to obtain the atomizing solvent.

21. The method for preparing the nicotine replacement liquid preparation according to claim 20, characterized in that: The step of adding flavoring is also included.

22. The method for preparing the nicotine replacement liquid preparation according to claim 20 or 21, characterized in that: The method further comprises the step of adding an organic acid.

23. Use of the nicotine replacement liquid preparation according to any one of claims 1 to 19 or the nicotine replacement liquid preparation prepared by the preparation method according to any one of claims 20 to 22 in an atomization device.

24. The use according to claim 23, characterized in that The atomization device is an electronic atomization device.

Images